TY - JOUR T1 - European Multicenter Study for the Evaluation of a Dual-Layer Flow-Diverting Stent for Treatment of Wide-Neck Intracranial Aneurysms: The European Flow-Redirection Intraluminal Device Study JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 841 LP - 847 DO - 10.3174/ajnr.A5592 VL - 39 IS - 5 AU - M. Killer-Oberpfalzer AU - N. Kocer AU - C.J. Griessenauer AU - H. Janssen AU - T. Engelhorn AU - M. Holtmannspötter AU - J.H. Buhk AU - T. Finkenzeller AU - G. Fesl AU - J. Trenkler AU - W. Reith AU - A. Berlis AU - K. Hausegger AU - M. Augustin AU - C. Islak AU - B. Minnich AU - M. Möhlenbruch Y1 - 2018/05/01 UR - http://www.ajnr.org/content/39/5/841.abstract N2 - BACKGROUND AND PURPOSE: Endoluminal reconstruction with flow-diverting stents represents a widely accepted technique for the treatment of complex intracranial aneurysms. This European registry study analyzed the initial experience of 15 neurovascular centers with the Flow-Redirection Intraluminal Device (FRED) system.MATERIALS AND METHODS: Consecutive patients with intracranial aneurysms treated with the FRED between February 2012 and March 2015 were retrospectively reviewed. Complications and adverse events, transient and permanent morbidity, mortality, and occlusion rates were evaluated.RESULTS: During the defined study period, 579 aneurysms in 531 patients (median age, 54 years; range, 13–86 years) were treated with the FRED. Seven percent of patients were treated in the acute phase (≤3 days) of aneurysm rupture. The median aneurysm size was 7.6 mm (range, 1–36.6 mm), and the median neck size 4.5 mm (range, 1–30 mm). Angiographic follow-up of >3 months was available for 516 (89.1%) aneurysms. There was progressive occlusion witnessed with time, with complete occlusion in 18 (20%) aneurysms followed for up to 90 ± 14 days, 141 (82.5%) for 180 ± 20 days, 116 (91.3%) for 1 year ± 24 days, and 122 (95.3%) aneurysms followed for >1 year. Transient and permanent morbidity occurred in 3.2% and 0.8% of procedures, respectively. The overall mortality rate was 1.5%.CONCLUSIONS: This retrospective study in real-world patients demonstrated the safety and efficacy of the FRED for the treatment of intracranial aneurysms. In most cases, treatment with a single FRED resulted in complete angiographic occlusion at 1 year.ASPIReAneurysm Study of Pipeline in an Observational RegistryEuFREDEuropean Flow-Redirection Intraluminal Device StudyFREDFlow-Redirection Intraluminal DevicePUFSPipeline for Uncoilable or Failed Aneurysms Study ER -